Stephen Liu, MD, on the Potential Treatment Impact of Amivantamab Plus Lazertinib in EGFR+ NSCLC at ASCO 2021

At ASCO 2021, Stephen Liu, MD, talked about treating patients with EGFR-mutant non–small cell lung cancer in the post-osimertinib setting with the combination of amivantamab and Lazertinib.

CancerNetwork® sat down with Stephen Liu, MD, of the Georgetown Lombardi Comprehensive Cancer Center, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to talk about treatments for patients with EGFR–mutant lung cancer following frontline osimertinib (Tagrisso). One such combination of amivantamab (Rybrevant) with lazertinib was presented at the meeting and may have the potential impact the care of patients following disease relpase.


At ASCO, [we saw] a lot of new data come out. One of the abstracts I [was] excited to see was number 9006. That one is looking at amivantamab with lazertinib after osimertinib progression for patients with EGFR-mutant lung cancer. For patients with advanced EGFR-mutant lung cancer, osimertinib has been our standard of care for many years now, but the [median] progression free survival of about 1 and a half years really leaves us wanting more. And at resistance, treatment options really fall off; the mechanisms of resistance after osimertinib are very heterogeneous. This strategy of combining a [tyrosine kinase inhibitor] with by specific antibody—like amivantamab, [which is] recently approved for EGFR exon 20[–positive] non–small cell lung cancer—could really give us a more exciting option after osimertinib. I really want to see the details, where we’re seeing responses, what types of responses, and what patients [have] seen those responses. I think that that has a chance to really impact care for EGFR-mutant lung cancer.


Bauml J, Cho B, Park K, et al. Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. ASCO Meeting Library. 2021. doi: 10.1200/JCO.2021.39.15_suppl.9006

Related Videos
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Shilpa Gupta, MD, shares the current standard of care for muscle-invasive bladder cancer and highlights other options that may be suitable for some patients.
An expert from Stanford Medicine that the goal behind a study characterizing circulating tumor DNA and its predictive value is to eventually replace blood marrow exams with a blood draw for those with multiple myeloma.
Related Content